亘喜生物宣布公司股东正式投票表决通过了与阿斯利康的并购协议

Core Viewpoint - Gracell Biotech has received shareholder approval for a merger agreement with AstraZeneca Treasury Limited, which is expected to be completed around February 22, 2024, resulting in Gracell becoming a private company and delisting its American Depositary Shares (ADS) from public trading [1][2]. Group 1: Merger Agreement - The special shareholder meeting held on February 19, 2024, resulted in approximately 99.9% of shareholders voting in favor of the merger agreement and related plans [2]. - The merger will involve Gracell being integrated into AstraZeneca Treasury Limited, with Gracell continuing as a wholly-owned subsidiary [1][2]. Group 2: Company Overview - Gracell Biotech is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer and autoimmune diseases [1][3]. - The company utilizes its proprietary FasTCAR and TruUCAR technology platforms, along with the SMART CART™ technology module, to address significant challenges in CAR-T therapies, including production time, cell quality, and treatment costs [3]. - Gracell's core product, BCMA/CD19 dual-target FasTCAR-T GC012F, is currently undergoing clinical trials for treating multiple myeloma, B-cell non-Hodgkin lymphoma, and systemic lupus erythematosus [3].